Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 57 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NVrZWY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\QN5BKSzVyPUCuNFAxOjh5IN88US=> MXnTRW5ITVJ?
LC-2-ad MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMECwN|E4KM7:TR?= MWTTRW5ITVJ?
RL95-2 M4\1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vrWmlEPTB;MD6wNFA3PjhizszN NUXsSXVbW0GQR1XS
MZ1-PC NX3Hcpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXoTWM2OD1yLkCwNFczQSEQvF2= MlXxV2FPT0WU
TE-8 M4PCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXjOWR1UUN3ME2wMlAxOTF5IN88US=> NIn3eYFUSU6JRWK=
SW954 NWH6VnpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;WWYJ3UUN3ME2wMlAxOTF7IN88US=> M2Lle3NCVkeHUh?=
TE-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn35TWM2OD1yLkCwNVI{KM7:TR?= MVHTRW5ITVJ?
PSN1 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnMR4hqUUN3ME2wMlAxOTNizszN MXfTRW5ITVJ?
MOLT-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHCTWM2OD1yLkCwNVQ6KM7:TR?= NEn3eYdUSU6JRWK=
697 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\UU3F4UUN3ME2wMlAxOTVizszN NWXLVGJXW0GQR1XS
ETK-1 M1qxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHRUJRKSzVyPUCuNFAyPTJizszN NE\KeGxUSU6JRWK=
TE-10 NXTye3MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXqRoxbUUN3ME2wMlAxOTV2IN88US=> M2nVVHNCVkeHUh?=
HUTU-80 M2TtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTiTWM2OD1yLkCwNVY5KM7:TR?= M2HyfHNCVkeHUh?=
NTERA-S-cl-D1 NXu3N4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[3cGlEPTB;MD6wNFIxQSEQvF2= MnTQV2FPT0WU
MFH-ino Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXFTWM2OD1yLkCwNlY5KM7:TR?= NGfIW4ZUSU6JRWK=
IA-LM NYrjeYI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMECyPEDPxE1? Mn3TV2FPT0WU
MC116 M{jmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXIeGdKSzVyPUCuNFAzQDlizszN M1f1S3NCVkeHUh?=
RKO NGjvTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vZUGlEPTB;MD6wNFI6QCEQvF2= NIjUdIVUSU6JRWK=
MRK-nu-1 NYTKWZduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32xVGlEPTB;MD6wNFI6QSEQvF2= M4m2e3NCVkeHUh?=
VA-ES-BJ NEfYUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;YSnRKSzVyPUCuNFA{KM7:TR?= NYKwN3pMW0GQR1XS
KALS-1 NFjGdGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:2NGlEPTB;MD6wNFMxQCEQvF2= M{DU[nNCVkeHUh?=
BB30-HNC NX[wSW1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn2TWM2OD1yLkCwN|E1KM7:TR?= MnP5V2FPT0WU
ACN Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfTTWM2OD1yLkCwN|E3KM7:TR?= M{K1XHNCVkeHUh?=
TE-9 M4mwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfKTWM2OD1yLkCwN|I3KM7:TR?= NVrtcHFpW0GQR1XS
SIG-M5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3hTWM2OD1yLkCwN|I4KM7:TR?= M{Hr[3NCVkeHUh?=
no-10 NVTGfpkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nzXWlEPTB;MD6wNFM3OiEQvF2= NEjoT5FUSU6JRWK=
EW-1 NY\Pdph1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHlN4ZFUUN3ME2wMlAxOzdzIN88US=> NUTLWo82W0GQR1XS
SK-LMS-1 NYezOIttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHKTWM2OD1yLkCwOFAyKM7:TR?= M{j2RnNCVkeHUh?=
GT3TKB MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonXTWM2OD1yLkCwOFM1KM7:TR?= MljkV2FPT0WU
ES4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHOTWM2OD1yLkCwOFQ6KM7:TR?= M13MUHNCVkeHUh?=
IMR-5 M{\ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHoTWM2OD1yLkCwOFUh|ryP NF;rdZVUSU6JRWK=
NCI-H1648 M3PhO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rqW2lEPTB;MD6wNFQ3QSEQvF2= NV7pXIQ{W0GQR1XS
MV-4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEC0O|Uh|ryP M1zoPXNCVkeHUh?=
SK-UT-1 NWjOV5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXWc5VEUUN3ME2wMlAxPDhizszN NEDqUm5USU6JRWK=
NB13 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\v[mlEPTB;MD6wNFQ6OSEQvF2= MYnTRW5ITVJ?
DJM-1 M1fkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEC1N{DPxE1? MlfHV2FPT0WU
ES8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm4OWRpUUN3ME2wMlAxPTN6IN88US=> MVHTRW5ITVJ?
TE-6 M2[xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT6TWM2OD1yLkCwOVch|ryP M1m2fXNCVkeHUh?=
KS-1 NFG4U3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr4TWM2OD1yLkCwOVgzKM7:TR?= NXvqTIRPW0GQR1XS
TE-1 M3vCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyyd49KSzVyPUCuNFA3ODZizszN MlXLV2FPT0WU
ATN-1 NUHFRYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEC2NFkh|ryP MoTQV2FPT0WU
A4-Fuk M3;admdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEC2NVEh|ryP M{XFRnNCVkeHUh?=
ALL-PO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELKXoNKSzVyPUCuNFA3OyEQvF2= MVfTRW5ITVJ?
BE-13 NHmydGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\vUWlEPTB;MD6wNFY{PiEQvF2= MnrwV2FPT0WU
KM12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;qdIoxUUN3ME2wMlAxPjN5IN88US=> NEjISm5USU6JRWK=
NOS-1 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXBTWM2OD1yLkCwOlUh|ryP MWPTRW5ITVJ?
SW962 NXP2PJJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf4TWM2OD1yLkCwOlYzKM7:TR?= NXXvRoRzW0GQR1XS
OCUB-M NIXlZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnUUYpKSzVyPUCuNFA3PjJizszN NV3IW5hnW0GQR1XS
NCI-H510A NUG0Rpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMEC2OlUh|ryP NF22WG9USU6JRWK=
EW-16 M3\FRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzoVHBUUUN3ME2wMlAxPjl2IN88US=> NWDzfoNbW0GQR1XS
KGN NFW5OXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjqTWM2OD1yLkCwO|EzKM7:TR?= MXLTRW5ITVJ?
LS-411N Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfROZpIUUN3ME2wMlAxPzF5IN88US=> Ml6wV2FPT0WU
Becker NXXtcVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzBT3FKSzVyPUCuNFA4OiEQvF2= MmjZV2FPT0WU
HC-1 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3p[HVQUUN3ME2wMlAxPzJzIN88US=> MVjTRW5ITVJ?
CESS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEC3N|ch|ryP MnfnV2FPT0WU
KURAMOCHI MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvkNmhEUUN3ME2wMlAxPzR6IN88US=> NWjiZ4J4W0GQR1XS
TGBC24TKB NYTTWlVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3mSpZKSzVyPUCuNFA4PTJizszN MXLTRW5ITVJ?
SW982 MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLLNmxKSzVyPUCuNFA4PjZizszN Mn7uV2FPT0WU
HCE-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe5PYxKSzVyPUCuNFA4PjdizszN NF\hZZlUSU6JRWK=
LOUCY MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEC3O|Uh|ryP M3PHO3NCVkeHUh?=
8-MG-BA NUnRUVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMEC3PVYh|ryP MY\TRW5ITVJ?
HT-144 NXzKeYliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPENVBKSzVyPUCuNFA5KM7:TR?= MYXTRW5ITVJ?
LXF-289 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETZV|JKSzVyPUCuNFA5OThizszN MmS0V2FPT0WU
RS4-11 NFnJZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnSd2RKSzVyPUCuNFA5OzZizszN NXnsc2JoW0GQR1XS
DEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxb3RUUUN3ME2wMlAxQDR3IN88US=> NFjjXXRUSU6JRWK=
OCI-AML2 NIj0fWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrZRVNmUUN3ME2wMlAxQDV{IN88US=> NYX0So1PW0GQR1XS
CCRF-CEM NFrzc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEC4O|Eh|ryP NXi5bG1TW0GQR1XS
A388 M3r2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvSd5BNUUN3ME2wMlAxQDd2IN88US=> MnvCV2FPT0WU
KNS-42 NInHWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDWTXNKSzVyPUCuNFA5QTFizszN NHXHTmpUSU6JRWK=
OVCAR-4 NWLyTZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HRT2lEPTB;MD6wNFkxPCEQvF2= MXPTRW5ITVJ?
NCI-H1355 NFzsVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEC5NVQh|ryP MUDTRW5ITVJ?
BL-70 M2izVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL1TWM2OD1yLkCwPVMh|ryP NFrZNFFUSU6JRWK=
BL-41 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjsOmtKUUN3ME2wMlAxQTN2IN88US=> M3zuTnNCVkeHUh?=
A101D NIrRZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7jN5pKSzVyPUCuNFA6PiEQvF2= M4rUZXNCVkeHUh?=
HL-60 NXXEN3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvTTWM2OD1yLkCwPVY3KM7:TR?= MXvTRW5ITVJ?
COR-L279 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMEC5PVkh|ryP M{TFeHNCVkeHUh?=
NCI-SNU-16 NEXiNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWntOJNqUUN3ME2wMlAyODB6IN88US=> M1;DUXNCVkeHUh?=
Calu-6 MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSweG9KSzVyPUCuNFExOTJizszN MV;TRW5ITVJ?
SR MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG0TWM2OD1yLkCxNFI3KM7:TR?= NH7odnpUSU6JRWK=
QIMR-WIL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK4dIIyUUN3ME2wMlAyODN|IN88US=> NH\ifHRUSU6JRWK=
LB647-SCLC M3Xtemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnyfVhKSzVyPUCuNFExPTFizszN MkLMV2FPT0WU
RPMI-8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj4S2tGUUN3ME2wMlAyOTB{IN88US=> NIfRc4RUSU6JRWK=
SK-PN-DW NUfXSIlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTRTWM2OD1yLkCxNVEzKM7:TR?= NX3DZlBHW0GQR1XS
SF268 NYjj[ldyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEGxOVEh|ryP NFjYcIVUSU6JRWK=
HD-MY-Z NGjjbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P0[GlEPTB;MD6wNVE3OyEQvF2= MV7TRW5ITVJ?
DOHH-2 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHPTWM2OD1yLkCxNlA{KM7:TR?= NHmzS4ZUSU6JRWK=
SCC-3 MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\STWM2OD1yLkCxNlA1KM7:TR?= MkXVV2FPT0WU
ST486 NHHNOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEGyNFQh|ryP M4f2VHNCVkeHUh?=
NALM-6 NGPR[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEGyNVQh|ryP M4n5fnNCVkeHUh?=
NCI-H1436 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvHTWM2OD1yLkCxNlMyKM7:TR?= NYnSSVBFW0GQR1XS
KE-37 M13Mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEGyN|Qh|ryP MYXTRW5ITVJ?
RPMI-8402 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEGyOVYh|ryP M4DQWXNCVkeHUh?=
RXF393 NVHZR5oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEGyOVch|ryP NGD2NYtUSU6JRWK=
KARPAS-45 M{Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfCTWM2OD1yLkCxNlch|ryP MlTTV2FPT0WU
HOP-62 M1rrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEGyO|Yh|ryP NWTKc3FXW0GQR1XS
ES1 NV\EXnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjad4hQUUN3ME2wMlAyOjh6IN88US=> Ml7mV2FPT0WU
L-363 NHzvcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDjTJRKSzVyPUCuNFE{PTFizszN MWTTRW5ITVJ?
GI-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVixR5BjUUN3ME2wMlAyOzd|IN88US=> MV\TRW5ITVJ?
CTV-1 NVO3WpdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXTS4ZKSzVyPUCuNFE1PzhizszN Mkn3V2FPT0WU
TE-5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEG0PVYh|ryP Mly4V2FPT0WU
SNU-C2B NIHKeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEG0PVYh|ryP Mn\EV2FPT0WU
K-562 M{jEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTYemo{UUN3ME2wMlAyPTF4IN88US=> NGX2dJFUSU6JRWK=
SNB75 M2XOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[xTmVkUUN3ME2wMlAyPTRizszN M{KwPHNCVkeHUh?=
MOLT-13 NEfPfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonxTWM2OD1yLkCxOlM4KM7:TR?= NF3IXIJUSU6JRWK=
LS-123 NHPkZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPrZ|JPUUN3ME2wMlAyPjZ2IN88US=> Mn7RV2FPT0WU
NCI-SNU-5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEG3NFEh|ryP NYjTNlRvW0GQR1XS
Daudi NFrWPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml21TWM2OD1yLkCxO|A5KM7:TR?= NGLVT4tUSU6JRWK=
A253 Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEG3N|gh|ryP M2G3e3NCVkeHUh?=
TGBC1TKB MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXMcolKSzVyPUCuNFE4PTJizszN NISxU|RUSU6JRWK=
SJSA-1 M{HKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HCSmlEPTB;MD6wNVc3PyEQvF2= NYXh[5F1W0GQR1XS
NCCIT M{\Nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjBXIZ4UUN3ME2wMlAyPzZ7IN88US=> NX;oU|BFW0GQR1XS
NCI-H69 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HVeGlEPTB;MD6wNVc4QCEQvF2= MVjTRW5ITVJ?
SH-4 M4TSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEG4PVUh|ryP M3nJc3NCVkeHUh?=
HCC1187 NYDGdnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMEG5NlQh|ryP MWHTRW5ITVJ?
HCC1599 NVrKeXRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHnfllKSzVyPUCuNFIxOiEQvF2= NXy4cZBiW0GQR1XS
ONS-76 NF7VXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLaTWM2OD1yLkCyNFM3KM7:TR?= M4LuWHNCVkeHUh?=
KU812 NE\pfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7kO45KSzVyPUCuNFIxOzlizszN Ml3WV2FPT0WU
ML-2 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULBUW0yUUN3ME2wMlAzODR5IN88US=> MkLJV2FPT0WU
HCE-T NHPrUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;OTWM2OD1yLkCyNFkzKM7:TR?= NGP2XGZUSU6JRWK=
NCI-H446 NUXVU3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXRTWM2OD1yLkCyNVEzKM7:TR?= NI\VU4hUSU6JRWK=
RPMI-6666 NIf6WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPETWM2OD1yLkCyNVQ6KM7:TR?= NIfqOGZUSU6JRWK=
MOLT-16 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXJTWM2OD1yLkCyNVU{KM7:TR?= MYfTRW5ITVJ?
JiyoyeP-2003 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMEKxO|Yh|ryP MVvTRW5ITVJ?
MHH-PREB-1 M2HiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml72TWM2OD1yLkCyNVkyKM7:TR?= MnnVV2FPT0WU
MC-CAR MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEKzNlYh|ryP MYjTRW5ITVJ?
BC-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDWbm9[UUN3ME2wMlAzOzR2IN88US=> NV3hfpl1W0GQR1XS
KINGS-1 NEHK[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITNOHdKSzVyPUCuNFI{PTVizszN MXzTRW5ITVJ?
PF-382 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofWTWM2OD1yLkCyN|c5KM7:TR?= NFnnVGJUSU6JRWK=
J-RT3-T3-5 MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T3[mlEPTB;MD6wNlM5OyEQvF2= M4jpV3NCVkeHUh?=
SF539 M37mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEK0NFEh|ryP NVHpfIhIW0GQR1XS
LB831-BLC M2K4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzlZ|hKSzVyPUCuNFI1QDVizszN MlHrV2FPT0WU
DMS-114 M{PkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\oT41KSzVyPUCuNFI2ODJizszN M1\CTXNCVkeHUh?=
LB1047-RCC M3PFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjrco9KSzVyPUCuNFI2OSEQvF2= MUPTRW5ITVJ?
LB771-HNC M1jPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrsXFBKSzVyPUCuNFI2OzRizszN MWjTRW5ITVJ?
BB65-RCC NF3W[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETQTmxKSzVyPUCuNFI2OzRizszN NX3ld3RvW0GQR1XS
BV-173 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi3VWxKSzVyPUCuNFI2PTRizszN MWfTRW5ITVJ?
ARH-77 M{P6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y2T2lEPTB;MD6wNlYxOSEQvF2= MUjTRW5ITVJ?
IST-MEL1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j4b2lEPTB;MD6wNlYzOyEQvF2= MmTPV2FPT0WU
NB1 NIfBcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEK2PFch|ryP MVLTRW5ITVJ?
EoL-1-cell NYrIO|BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEK2PFgh|ryP MVzTRW5ITVJ?
KY821 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P2dWlEPTB;MD6wNlY6PyEQvF2= M174WXNCVkeHUh?=
CMK NFXoeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLuPFYxUUN3ME2wMlAzPzN2IN88US=> NGrSSFNUSU6JRWK=
NCI-H2126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzTTWM2OD1yLkCyO|Y5KM7:TR?= NXvmbm5vW0GQR1XS
NCI-H526 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMEK4PVEh|ryP M3THTnNCVkeHUh?=
COLO-684 M2LscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\DTWM2OD1yLkCyPVA5KM7:TR?= MmLoV2FPT0WU
NCI-H747 M4\UWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXESnpKSzVyPUCuNFI6OzNizszN NELve5hUSU6JRWK=
JAR NULsO4F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fWbmlEPTB;MD6wNlk1PiEQvF2= MXzTRW5ITVJ?
MEG-01 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPtSpRUUUN3ME2wMlAzQTd6IN88US=> M4HoXnNCVkeHUh?=
MONO-MAC-6 M1fkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfqUVdKSzVyPUCuNFMxOjNizszN NIGwNZBUSU6JRWK=
IST-SL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvTXmZEUUN3ME2wMlA{ODR{IN88US=> MWTTRW5ITVJ?
CPC-N NU\DTGpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfHNWpKSzVyPUCuNFMxPzlizszN MW\TRW5ITVJ?
NCI-H1963 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7IfYxKSzVyPUCuNFMyOzFizszN M{fX[XNCVkeHUh?=
K052 NEPG[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nOTGlEPTB;MD6wN|I1PyEQvF2= M4XVWHNCVkeHUh?=
KM-H2 M2q4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrTeYwzUUN3ME2wMlA{OzB5IN88US=> NWfGcpo2W0GQR1XS
TE-12 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPQTWM2OD1yLkCzN|A6KM7:TR?= MW\TRW5ITVJ?
TK10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m4Z2lEPTB;MD6wN|M2PiEQvF2= NYfORohiW0GQR1XS
NMC-G1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrRO5hKSzVyPUCuNFM1PTJizszN MV\TRW5ITVJ?
no-11 NVPXXm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEO0O|gh|ryP NV25flFIW0GQR1XS
NCI-H524 NHLkT|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEO1Nlkh|ryP MVTTRW5ITVJ?
MHH-CALL-2 Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf5clVKSzVyPUCuNFM2PjJizszN NIHzfnRUSU6JRWK=
GB-1 M2D4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEO2JO69VQ>? NEWyTJBUSU6JRWK=
OPM-2 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi3TWM2OD1yLkCzOlc{KM7:TR?= M4fXeHNCVkeHUh?=
RH-1 M2rnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XRUGlEPTB;MD6wN|gyQSEQvF2= NXWzWmtzW0GQR1XS
NCI-H64 M1PEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEO4OVch|ryP M1zLPHNCVkeHUh?=
EVSA-T NX\XTog4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEO5NlMh|ryP MUDTRW5ITVJ?
KARPAS-299 NIL3Zo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIixZ2hKSzVyPUCuNFM6QCEQvF2= NFLWU5JUSU6JRWK=
MZ7-mel MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMESwOEDPxE1? M2nscnNCVkeHUh?=
LB373-MEL-D MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMESxNFUh|ryP NX;wVWRlW0GQR1XS
HEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[zTWM2OD1yLkC0NVQh|ryP M{TBdnNCVkeHUh?=
SW872 NFnqTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHhTWM2OD1yLkC0NlEh|ryP NX\HRW9yW0GQR1XS
DU-4475 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrCO4pKSzVyPUCuNFQzPDRizszN Mk[4V2FPT0WU
IST-SL2 NEWzUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfqdXRKSzVyPUCuNFQzPzVizszN MmHHV2FPT0WU
NCI-H82 NYK0bYVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH4ZnRKSzVyPUCuNFQ{ODdizszN NIP4cGVUSU6JRWK=
LC4-1 M3PTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TQTWlEPTB;MD6wOFM2OSEQvF2= MX\TRW5ITVJ?
HDLM-2 M3LH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfsTWM2OD1yLkC0N|kzKM7:TR?= MkfzV2FPT0WU
MMAC-SF MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fVT2lEPTB;MD6wOFU{PCEQvF2= NH;Gd3dUSU6JRWK=
L-540 NXLTU4lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln4TWM2OD1yLkC0OlM6KM7:TR?= NWTSR3pzW0GQR1XS
MZ2-MEL NWnUdYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzzW4tVUUN3ME2wMlA1PzR{IN88US=> MUnTRW5ITVJ?
LU-134-A NF7ZcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[2d|lKSzVyPUCuNFQ4PzNizszN NVLEXJJtW0GQR1XS
UACC-257 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\1NGlEPTB;MD6wOFg1QSEQvF2= NXLOc4ZnW0GQR1XS
NCI-H1581 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLPNGZKSzVyPUCuNFQ6PTNizszN NFHpWmhUSU6JRWK=
NB17 NFzhS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGxTWM2OD1yLkC0PVc6KM7:TR?= MWrTRW5ITVJ?
SBC-1 NIjZbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PkcGlEPTB;MD6wOVA1OiEQvF2= NFjrT5FUSU6JRWK=
TALL-1 MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXOTWM2OD1yLkC1NFQ2KM7:TR?= NVy4OmNrW0GQR1XS
NCI-H1304 NWDkXop6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEWyNFgh|ryP NWDtfIJUW0GQR1XS
NEC8 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonYTWM2OD1yLkC1Nlg3KM7:TR?= MlvvV2FPT0WU
CAL-148 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXSe4tKSzVyPUCuNFU1OzlizszN NGfvc3lUSU6JRWK=
CGTH-W-1 NWDKO2ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjsTWM2OD1yLkC1OFQ6KM7:TR?= M1zHPHNCVkeHUh?=
NCI-H889 NVfhfGhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[yTWM2OD1yLkC1OVkzKM7:TR?= NIHuU4xUSU6JRWK=
GR-ST NGPtfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO3UXo{UUN3ME2wMlA2PjJzIN88US=> NGLYOHZUSU6JRWK=
KARPAS-422 M3rsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPwbW1KSzVyPUCuNFU3PSEQvF2= NIj0bIFUSU6JRWK=
RPMI-8866 NFTyWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XhVWlEPTB;MD6wOVcyOiEQvF2= NGnZdndUSU6JRWK=
SCLC-21H Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jnfmlEPTB;MD6wOVg5PCEQvF2= M2roZ3NCVkeHUh?=
COR-L88 M{TMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvNTWM2OD1yLkC1PVI4KM7:TR?= MWHTRW5ITVJ?
LU-139 NFXQZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r3SmlEPTB;MD6wOVk5PiEQvF2= NELjXVBUSU6JRWK=
SF126 NEjBS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrN[HVKSzVyPUCuNFYyOzNizszN M1TwcXNCVkeHUh?=
NCI-H1882 NEDvSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTUTWM2OD1yLkC2OFI1KM7:TR?= M{jIVHNCVkeHUh?=
EW-24 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLNdG9KSzVyPUCuNFY1QDNizszN NXfsWoE1W0GQR1XS
CP67-MEL NVviTZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;5d5lbUUN3ME2wMlA3QDFizszN M16xZnNCVkeHUh?=
DG-75 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonUTWM2OD1yLkC2PFk6KM7:TR?= NHTD[ZZUSU6JRWK=
LOXIMVI MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPGSJo5UUN3ME2wMlA4ODJ6IN88US=> NX7mVZl5W0GQR1XS
HH NH7McFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj5cXRwUUN3ME2wMlA4OTV5IN88US=> M3zLW3NCVkeHUh?=
K5 NYHmcJZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojmTWM2OD1yLkC3NlI3KM7:TR?= NWi3e3lmW0GQR1XS
EC-GI-10 M4P4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEeyOVch|ryP MoryV2FPT0WU
SK-N-DZ NVX0NIZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\wfJBKSzVyPUCuNFc{ODdizszN NXXJUIllW0GQR1XS
A3-KAW NU[5PHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\3TWM2OD1yLkC3N|UyKM7:TR?= MUDTRW5ITVJ?
MLMA NHX0eYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj2TWM2OD1yLkC3OFY2KM7:TR?= MmLpV2FPT0WU
LB996-RCC Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrBPI96UUN3ME2wMlA4PzB5IN88US=> MWXTRW5ITVJ?
OS-RC-2 NInrS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHXTmlKSzVyPUCuNFc4PDhizszN MWDTRW5ITVJ?
CTB-1 NGH6UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\pU5hKSzVyPUCuNFc5OSEQvF2= MmfwV2FPT0WU
IST-MES1 M2\t[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfNTWM2OD1yLkC3PVEzKM7:TR?= NHriWJVUSU6JRWK=
LS-1034 M2PZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPvc4p[UUN3ME2wMlA5ODN3IN88US=> NEPifoFUSU6JRWK=
HT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPjU41tUUN3ME2wMlA5ODh4IN88US=> M2mwS3NCVkeHUh?=
NCI-H2141 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7xT3VKSzVyPUCuNFgyKM7:TR?= NGrJPYFUSU6JRWK=
LB2518-MEL NVOyb3ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfLWlFEUUN3ME2wMlA5OTRzIN88US=> NE[4NXZUSU6JRWK=
GI-ME-N M1zrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LU[2lEPTB;MD6wPFQ2OiEQvF2= MnLXV2FPT0WU
TGW NF;OZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XUcGlEPTB;MD6wPFYxPyEQvF2= NEH4NFlUSU6JRWK=
SK-NEP-1 M3XJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvWZ416UUN3ME2wMlA5PjRzIN88US=> NHfCR5hUSU6JRWK=
NOMO-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTWTWM2OD1yLkC5Nlc2KM7:TR?= M2DVWnNCVkeHUh?=
ES6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMEm1PFkh|ryP NGO0TZlUSU6JRWK=
NCI-H209 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DwRmlEPTB;MD6wPVc5PiEQvF2= M3HZbXNCVkeHUh?=
GAK NFzj[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOyTWM2OD1yLkGwNVYh|ryP MYnTRW5ITVJ?
BC-1 NXKwV2hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HxXmlEPTB;MD6xNFM3OSEQvF2= MX3TRW5ITVJ?
KLE NHXpc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\3TWM2OD1yLkGwOFQ{KM7:TR?= MUDTRW5ITVJ?
EW-3 NUfrTI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r6VmlEPTB;MD6xNFk5KM7:TR?= NF[0TY5USU6JRWK=
NKM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMUGxJO69VQ>? NG\ZTlVUSU6JRWK=
D-336MG NUTuNGlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjzdWhsUUN3ME2wMlEyOjR2IN88US=> MkX1V2FPT0WU
NB69 NVK0bVV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\6ZVJKSzVyPUCuNVE{ODFizszN NVfaXo9ZW0GQR1XS
D-263MG MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMUG3NVIh|ryP MmfVV2FPT0WU
KP-N-YS M4WwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMUKyPVEh|ryP MWrTRW5ITVJ?
NCI-H1155 M2HKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\kcHRKSzVyPUCuNVI2PThizszN M2fmenNCVkeHUh?=
BOKU NI[1NXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j5PGlEPTB;MD6xNlU4QSEQvF2= Mli5V2FPT0WU
LAMA-84 NWThU4kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTSTWM2OD1yLkGyPVkh|ryP M4O2[HNCVkeHUh?=
Raji MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\EemlEPTB;MD6xN|EyPyEQvF2= NECy[GdUSU6JRWK=
LU-65 M324OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjlTWM2OD1yLkGzN|A4KM7:TR?= MYnTRW5ITVJ?
NCI-H187 NVnVcG9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKzPItHUUN3ME2wMlE{QTJ2IN88US=> NXPGdlV[W0GQR1XS
GCIY NXLHbJduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;2OGlEPTB;MD6xOFkxOSEQvF2= MXnTRW5ITVJ?
NCI-H2107 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfTTWM2OD1yLkG1NFgh|ryP MmnSV2FPT0WU
NCI-H1522 M17tTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3wTWM2OD1yLkG1NlY3KM7:TR?= MUnTRW5ITVJ?
NB6 NYXqXYt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf5XmlIUUN3ME2wMlE2PjJ|IN88US=> NH3ZPWtUSU6JRWK=
EM-2 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMUW3NFYh|ryP NFvqSoZUSU6JRWK=
HCC2218 M1juT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTHUFdKSzVyPUCuNVU6QCEQvF2= MmW1V2FPT0WU
NCI-H748 NYPmSlZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TSRWlEPTB;MD6xOlM4PiEQvF2= NI[xSJlUSU6JRWK=
MS-1 M1GxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2yOFBKSzVyPUCuNVY2OzdizszN MUPTRW5ITVJ?
NB5 M336Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjTd3d4UUN3ME2wMlE3PTl5IN88US=> Ml3MV2FPT0WU
OMC-1 NIjRToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmyemJKSzVyPUCuNVY3QDhizszN M1rqW3NCVkeHUh?=
NCI-H345 M37hfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3NfIZtUUN3ME2wMlE3QTJ6IN88US=> M{f6RnNCVkeHUh?=
L-428 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;EU3RKSzVyPUCuNVY6PDVizszN MlPFV2FPT0WU
SCH NGC5cIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuwTWM2OD1yLkG4Olg2KM7:TR?= NEmyOoxUSU6JRWK=
NCI-H1417 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfoXYtKSzVyPUCuNVkzOjdizszN NHrEb4dUSU6JRWK=
COLO-320-HSR MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXNTWM2OD1yLkG5OVMzKM7:TR?= NWDvWVhHW0GQR1XS
BT-474 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMkC4PVIh|ryP M2nnSXNCVkeHUh?=
GDM-1 MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LCN2lEPTB;MD6yNVk4OSEQvF2= MXHTRW5ITVJ?
NCI-H2196 NXXMZWdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW1TWM2OD1yLkKyNlM2KM7:TR?= MlXyV2FPT0WU
KP-N-RT-BM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHpRoVKSzVyPUCuNlI{PDlizszN M4GzWHNCVkeHUh?=
KNS-81-FD NFL1SnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X5[mlEPTB;MD6yNlk2QCEQvF2= MWrTRW5ITVJ?
COLO-668 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTrW5lKSzVyPUCuNlM3PzVizszN NV2zSndZW0GQR1XS
C2BBe1 M3XPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMk[3OFch|ryP M1rCPXNCVkeHUh?=
Ramos-2G6-4C10 NH7aVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMk[5OVQh|ryP NWP4emhXW0GQR1XS
CAS-1 NU\YVop3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NESxXIlKSzVyPUCuNlcxQTZizszN MVLTRW5ITVJ?
GOTO M4fGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jWTGlEPTB;MD6yO|g6PCEQvF2= NYO4N482W0GQR1XS
LP-1 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHETXh7UUN3ME2wMlI5ODV5IN88US=> MomwV2FPT0WU
NCI-SNU-1 NGPlVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCyS3dPUUN3ME2wMlI6PDJ{IN88US=> M4Lrb3NCVkeHUh?=
EB-3 NED0fJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMkm5O|kh|ryP NV;4cmN7W0GQR1XS
MHH-NB-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwM{C0NFIh|ryP MWPTRW5ITVJ?
SK-N-FI MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X6dGlEPTB;MD6zNVY6OiEQvF2= MVXTRW5ITVJ?
HCC2157 NXTVV41jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\pTWM2OD1yLkOzPVE{KM7:TR?= MU\TRW5ITVJ?
SIMA MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwM{S1PFEh|ryP NX3kOI97W0GQR1XS
MDA-MB-134-VI NVL3T|AxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jWOmlEPTB;MD6zOlkzQCEQvF2= NGLuVXZUSU6JRWK=
NCI-H1694 NYfk[phpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF6ze|JKSzVyPUCuN|ch|ryP NFHGcINUSU6JRWK=
EHEB MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwM{mwPFUh|ryP MmrXV2FPT0WU
U-266 M4TGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwM{m4OFYh|ryP MX7TRW5ITVJ?
LC-1F MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DDe2lEPTB;MD60N|c3PSEQvF2= MorMV2FPT0WU
SHP-77 NH\aOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X3TGlEPTB;MD60O|g2PSEQvF2= NE[3OnZUSU6JRWK=
LS-513 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPoNIRmUUN3ME2wMlQ6OzB5IN88US=> M2rvNHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID